LatchBio, which develops a web-based service for biologists to integrate, process, and visualize data, raises a $28M Series A co-led by Coatue and Lux Capital
Context & Ripple Effects
LatchBio's $28M Series A lands in a life-sciences software funding line that has been building for years: Benchling scaled from a $34.5M Series C to a $50M round at an $850M valuation for managing biotech research data, while Artificial raised a $21.5M Series A for lab R&D automation. The pattern is consistent — venture capital is funding the software layer around biological experiments, not just the experiments themselves.
LatchBio's angle within that layer is integration and visualization in the browser: rather than owning the system of record the way Benchling does, it positions itself as the place biologists pull data together and make sense of it, with Coatue and Lux Capital co-leading the bet.
First-order effects
- Benchling, the incumbent in biotech research data software, now faces a funded rival attacking from the adjacent integration-and-visualization layer rather than head-on, forcing a build-or-partner decision on that capability.
Second-order effects
- Coatue and Lux Capital's co-lead signals that generalist and deep-tech investors both see the bio-data tooling market as big enough for layered competition, which should push follow-on rounds for adjacent workflow tools like Artificial's lab-automation software.
Third-order effects
- As AI-driven biology tools mature — Cradle's AI protein-design raise is the clearest sign — the volume and heterogeneity of experimental data grows, structurally favoring the integration layer LatchBio occupies and pushing the category toward consolidation around whoever owns the data plumbing.
The trend: Life-sciences software is stratifying into specialized layers — data management, integration, lab automation, AI design — each attracting dedicated venture rounds rather than one platform absorbing the stack.